Amgen hit with a setback as Kyprolis fails a key frontline trial for multiple myeloma
Amgen reported early Tuesday that Kyprolis has failed a Phase III trial for frontline use against multiple myeloma, a setback that can only further …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
